Skip to main content

You are here

Home » News & Insights

News & Insights

Simon Goldman
Insights

Investor Q&A: Simon Goldman

UCLTF Investor, Simon Goldman tells us what led him to his current role at UCLTF and what he enjoys about working in technology...
International Women's Day
Insights

International Women's Day 2022

In celebration of International Women's Day, four women who work with UCLTF - Anne Lane (CEO, UCL Business), Pauline Stasiak...
Targeting LRG-1 in oncology
News

Epsilogen announces completion of oversubscribed £30.75m Series B finacing

Epsilogen Ltd., a global leader in the development of novel immunoglobin E (IgE) antibodies to treat cancer, announced it has...
Intrinsic
Insights

We're hurtling towards a computing impasse - the investments we make now will define our future

UCLTF Physical Science Investment Director, David Grimm, and Intrinsic's CTO, Adnan Mehonic discuss the future of investing...
Bramble
News

Bramble Energy secures £35 million to fund its game changing technology to support net zero mission

London-based fuel cell company Bramble Energy has closed a £35million investment round to help further expand its game changing...
Insights

Meet Pauline Stasiak, UCLTF Investor

Meet UCLTF's newest Investor, Pauline Stasiak, and find out about her career in investment and technology transfer.
Orchard
Insights

G-quadruplex licence showcases the UCLTF’s unique commercialisation model

UCLTF Investment Director, Simon Goldman discusses UCLTF's commercialisation model, in light of the recent announcement from...
News

Qualigen Therapeutics secures worldwide rights to G4-selective transcription inhibitors from UCL to develop as cancer therapeutics
p47-CGD
Insights

UCLTF's Fund Managers share their trend predictions for 2022

UCLTF's Fund Managers have shared their trend predictions for 2022, looking at which areas they think will see the most...
quantum computing
Insights

The rise of deeptech investments speak to an industry brimming with possibility

UCLTF's David Grimm and Tanel Ozdemir share their insights on the deeptech industry and its bright future.
Tanel Ozdemir
Insights

Investor Q&A: Tanel Ozdemir

UCLTF Investor, Tanel Ozdemir shares his thoughts on investing, and life as an academic.
Quell Therapeutics UCLTF
News

Quell Therapeutics raises $156 million in oversubscribed Series B financing

UCLTF portfolio company, Quell Therapeutics raises $156 million in oversubscribed Series B financing to advance its pioneering...
Insights

UCLTF Webinar: The state of early-stage Climate Tech investing
DNA Sequence
Insights

On not downclimbing: the state of the biotech market

UCLTF's Investment Director, Simon Goldman, looks at the state of the biotech market.
News

UCLTF invests in Carbon Re, a spinout helping energy-intensive industries reach Net Zero

Carbon Re, a spinout from UCL and Cambridge University, has secured £1m of funding to progress its AI technology which helps...
Phasecraft
News

Phasecraft improves Hamiltonian simulation algorithms for near-term quantum hardware

Phasecraft reveal their latest research in which they work one layer below the standard quantum circuit model to achieve a...
Tanel Ozdemir
Insights

Bringing immuno-oncology cell therapies to the masses – are we (nearly) there yet?

Scientists and clinicians within the immuno-oncology field have spent the last three decades demonstrating the remarkable...
David Grimm
Insights

David Grimm talks to Startup Dads podcast

David Grimm, UCLTF Investment Director, shares his experiences with podcast Startup Dads. He discusses how to be an empathetic...
UCLTF Showcase
Insights

UCLTF Showcase 2021 - The Highlights
Simon Goldman
Insights

A Window to the Past: Is the Biotech Investment Boom Going to Last?

The biotech industry has been going through a period of fast growth in recent years. To uncover whether the current biotech...
Apollo Therapeutics logo
Investment

UCL, Imperial College London and University of Cambridge are behind innovative industry university collaboration receiving £100m funding to rapidly advance cutting-edge science

Apollo Therapeutics, a unique collaboration between three leading universities (University College London, Imperial College and...
NovalGen Logo
News

NovalGen doses first patient in Phase I study in Chronic Lymphocytic Leukemia & Mantle Cell Lymphoma

– NVG-111 is the first-in-class T-cell engager that simultaneously binds CD3 on T-cell and ROR1 on tumor cells –
NovalGen Logo
News

NovalGen presents data at American Society of Clinical Oncology for novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma

London, United Kingdom, May 20, 2021 – NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer...
News

UCL Technology Fund secures partnership with Viralgen, leading gene therapy manufacturer

The UCL Technology Fund and Viralgen Vector Core, a Spanish CDMO offering best-in-class manufacturing for gene therapy, have...
News

NovalGen receives CTA approval to start a Phase 1/2 first in human study

NovalGen receives CTA approval to start a Phase 1/2 first in human study
Achilles
News

Achilles Therapeutics Announces Pricing of Initial Public Offering

London, UK 30 March 2021 – Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing...
Simon Goldman
Insights

Over the Hill and (still) far away for UK biotech companies

By Simon Goldman (pictured), Investment Director, UCL Technology Fund – This month’s Lord Hill review will do little to halt UK...
News

MedNous interviews Professor Amit Nathwani

MedNous recently interviewed Professor Amit Nathwani, Chief Executive Officer of UCLTF portfolio company NovalGen. He shares his...
Memristor Wafer
Investment

Intrinsic closes £1.35m seed funding round to prototype next generation memory devices

Memory innovator Intrinsic Semiconductor Technologies Ltd (“Intrinsic”) has announced the close of a £1.35m seed funding round...
David Grimm
Insights

Want to build a deeptech startup? Throw out the VC playbook

Every startup founder needs a good dose of grit, stamina and endurance to take a startup from idea to the heights of unicorn...
Insights

International Women’s Day 2021 – Meet Leigh Brody, UCLTF Investment Manager

To celebrate International Women's Day, we interviewed Leigh Brody, UCLTF Investment Manager.
axovia
Investment

Renowned Geneticist Philip Beales Launches Axovia Therapeutics to Develop Transformative Medicines for Ciliopathies

Axovia, an innovative gene therapy company developing disease-transformative medicines for ciliopathies, is a majority-owned...
NovalGen Logo
News

NovalGen enters strategic partnership with HALIX B.V. to manufacture clinical trial materials

London, United Kingdom and Leiden, The Netherlands, February 22nd 2021 – NovalGen Ltd. (“NovalGen”), a biopharmaceutical company...
Cells
Insights

Why you should consider manufacturing from the start of the biotech R&D process

Simon Goldman, February 2021 - One of the most important, yet under-appreciated aspects of biotech commercialisation is the...
Quell Therapeutics UCLTF
Investment

Quell Therapeutics Expands Series A Financing to $84 Million

Quell Therapeutics Ltd (“Quell”), a biotechnology company developing engineered T regulatory (Treg) cell therapies, today...
Targeting LRG-1 in ophthalmology
Insights

UCL Technology Fund talks to the PanAngium team

UCL Technology Fund's Simon Goldman talks to Academic Co-Founders of PanAngium, Professors Steve Moss and John Greenwood.
Insights

Platform technologies: going deep to go wide

Biomedical platform technologies are appealing because they can create impact (and therefore revenues) in multiple markets or...
Phasecraft
Investment

Phasecraft announces largest seed funding round for a UK quantum computing company and new technology breakthroughs

On the back of new quantum algorithm breakthroughs, Phasecraft has today closed a record seed round for a quantum computing...
Echopoint Medical
Insights

UCL Technology Fund talks to co-founders of Echopoint about all things startups, fundraising and VC

David Grimm, Director at the UCL Technology Fund talks to co-founders of Echopoint Malcolm Finlay and Adrien Desjardins.
Teacher with student
Investment

Third Space Learning raises £4.3m Series-A extension and announces a commercial partnership with China’s NetDragon to accelerate plans for international expansion.

Third Space Learning (TSL), the UK’s leading online tutoring company, has completed a £4.3m funding extension from existing...
Nozzle
Investment

Nozzle.ai raises $2.6m to accelerate adoption of AI platform with brands and sellers on Amazon

Nozzle.ai, an eCommerce and advertising optimisation platform for Amazon, has raised $2.6 million (£2 million) in funding from...
Orchard Therapeutics
Insights

UCL Technology Fund and Orchard Therapeutics: from idea to Nasdaq IPO and beyond

Dr Simon Goldman, interviews CEO of Orchard Therapeutics, Professor Bobby Gaspar.
Insights

An evolution in early stage gene therapy funding models
Two people searching at a laptop
News

We are recruiting a Life Sciences Investor for the UCL Technology Fund

We are recruiting a new Investment Manager to join the Life Sciences team within UCL Technology Fund.
Freeline Therapeutics   
News

Freeline Therapeutics makes its NASDAQ debut

Freeline Therapeutics Holdings plc (“Freeline”), a UCL Technology Fund portfolio company, has made its debut on NASDAQ in the...
Bramble Energy
Investment

Bramble energy secures significant new capital to accelerate its unique fuel cell deployment

Bramble Energy, the world’s most scalable hydrogen fuel cell company has raised a £5m Series A round. BGF led the round and was...
UCL Technology Fund Team
News

UCL Technology Fund announces first close of £100m Fund 2

UCL Technology Fund (UCLTF), managed by AlbionVC in collaboration with UCL Business (UCLB) (the university’s commercialisation...
Humanloop team
Investment

Humanloop raises funding to teach AI to learn from humans faster

Humanloop, a game changing UCL spinout, has attracted investment from UCL’s Technology Fund (UCLTF). Based on the world-leading...
COVID-19 Image
News

UCL engineering cancer antibody therapies for Covid-19

UCL’s Cancer Institute is repurposing a sophisticated antibody engineering approach, funded by the UCL Technology Fund (UCLTF),...
Epsilogen
Investment

Epsilogen Announces £3m Series A2 financing and licences MOv18 IgE, an anti-folate receptor alpha IgE antibody from King’s College London

Epsilogen Ltd (formerly known as IGEM Therapeutics), a global leader in the development of immunoglobulin E (IgE) antibodies to...
Investment

AstronauTx secures UCLTF investment for dementia therapeutics

AstronauTx Ltd, a biotech company developing new medicines designed to restore the normal behaviour of astrocytes for the...
News

Portfolio company Astroscreen featured in the Evening Standard

As the UK gears up for a potential election, there are concerns over the role disinformation will play in democracy
News

Quell Therapeutics makes FierceBiotech's 2019 Fierce 15

The list highlights biotech companies whose hard work and cutting-edge research aims to stop disease in its tracks.
Investment

Echopoint raises £2.8m to address the ‘grey zone’ of heart disease treatment

Echopoint Medical Ltd, a spinout company from UCL, has raised £2.8m to develop optical sensing technology to help heart disease...
Insights

Why we Invested in Quantum Computing start-up Phasecraft

There has been a leap in excitement about quantum computing in the last year thanks to the emergence of a new class of quantum...
Investment

Achilles Therapeutics raises £100m in Series B

Achilles Therapeutics (“Achilles”), a bio-pharmaceutical company developing personalised cancer immunotherapies, today announces...
News

Orchard Therapeutics Announces Update from POC Study of OTL-203

Orchard Therapeutics announced data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203...
Insights

UCL’s Centre for Amyloidosis and Acute Phase Proteins published in the Journal of Medicinal Chemistry

Ground-breaking work by Prof Alessandra Corazza, Prof Sir Mark Pepys, Prof Vittorio Bellotti and colleagues of the Wolfson Drug...
Insights

Funding academic innovations in advanced therapies: an interview with Simon Goldman

Simon Goldman, Investment Manager for UCLTF, talks to RegMedNet about funding academic innovation
UCL Technology Fund Brochure
Insights

2019 Brochure

Featuring fund highlights from the past year
Insights

Andrew Elder on healthtech investing

Andrew Elder talks to HS. about his journey from brain surgeon to venture capitalist, the history of healthtech investing and how...
News

UCL Technology Fund Showcase 2019

We would like to thank everyone who attended the 2019 UCL Technology Fund showcase. We hope the event provided some insight on...
News

Hazy wins 'Best Innovation in Data Protection & Privacy'

Hazy wins 'Best Innovation in Data Protection & Privacy' at the 2019 CogX awards.
quantum computing
Investment

Fund leads £750k investment in Phasecraft

The UCL Technology Fund led a £750k investment into Phasecraft, a pioneering quantum computing company, along with co-investors...
Quell Therapeutics UCLTF
Investment

UCLTF completes £1m investment into Quell Therapeutics as part of £35m Series A round

UCLTF £1m investment into Quell Therapeutics is part of a £35m Series A round led by Syncona
Odin Team
Investment

Odin Vision scales up its cancer detection technology

Innovative medtech company Odin Vision is to scale up its pioneering cancer detection technology thanks to an investment round...
GUV Award
News

UCLTF nominated for 'Investment Unit of the Year'

We are delighted to announce that the UCL Technology Fund has been nominated for Investment Unit of the Year by Global University...
Astroscreen
Investment

Astroscreen raises $1m to detect social media manipulation

UK-based start-up Astroscreen has secured $1M in initial funding to progress its pioneering technology which identifies carriers...
Orchard Therapeutics
News

Data Supports Achievement of Proof-of-Concept Milestone for OTL-300

Orchard Therapeutics has announced the achievement of clinical proof-of-concept based on data from the trial of OTL-300, for the...
Orchard Therapeutics
News

Orchard Therapeutics achieves 100% survival rate during trial treatment for ADA-SCID

Orchard Therapeutics, a commercial-stage biopharmaceutical company, presented their two-year follow-up data in 20 patients from...
Hazy
News

Hazy included in Forbes '15 Machine Learning Companies To Watch In Europe'

Hazy has been listed by Forbes as one of the Top 15 European Machine Learning companies to watch.
IGEM Therapeutics UCLF
Investment

IGEM Therapeutics Announces Final Close of £5m Series A Financing Round

New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM to continue development of IgE...
Orchard Therapeutics
News

Orchard Therapeutics announces closing of $225 Million Initial Public Offering

Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through...
Hazy Team Photo
Investment

UCL spin-out Hazy adds $1.8 million in seed funding

Hazy, the London-based AI company enabling ethical, effortless and GDPR-compliant data sharing for responsible businesses, has...
MeiraGTx
News

UCL Technology Fund investment MeiraGTx raises $75m at IPO

MeiraGTx is its first UCLTF investment to IPO
BloomsburyAI
Exit

Bloomsbury AI joins the Facebook Team in London

UCL Technology Fund is very proud to have backed Bloomsbury AI and we are delighted that they are joining the Facebook team.
Matr image of teacher and children.JPG
Investment

Matr raises £4.75 million for AI teaching platform

Matr, the online teaching platform, has announced it has closed a £4.75 million Series A investment round led by the UCL...
Freeline therapeutics.jpeg
News

Freeline secures over £88 million of funding

Freeline Therapeutics announces today that it has raised over £88 million of new capital in a Series B financing round
UCLTF Showcase 2018
Insights

UCL Technology Fund Showcase 2018

The inaugural UCL Technology Fund Showcase, held at Digital Catapult, brought together two years of investing in world-leading...
Glialign
Investment

UCL Technology Fund invests in cell therapy company Glialign

The UCL Technology Fund, UK Innovation & Science Seed Fund, alongside support from Innovate UK, have invested in UCL spinout...
Mediagamma2
Investment

UCL Technology Fund and ParkWalk invest in adtech machine learning company MediaGamma

The UCL Technology Fund has invested in MediaGamma, the predictive analytics software company, as part of a £2m round in...
p47-CGD
Investment

UCL Technology Fund has approved investment of up to £1m in the development of a gene therapy for p47-CGD

The UCL Technology Fund has approved an investment of up to £1m to support the development of a gene therapy for p47phox-...
Canbex
Investment

UCLTF fund drug development platform Canbex for the treatment of multiple sclerosis

Canbex was established to develop the VSN compound series, a drug development platform with potential applications in a wide...
Orchard Therapeutics
News

Orchard Therapeutics launches with £21-million series A funding round

Orchard Therapeutics has secured £21-million in Series A financing led by F-Prime with UCLTF. Orchard Therapeutics is a...
AlbionVC to manage UCLTF fund
News

Albion to Manage the UCL Technology Fund

Albion Capital, one of the largest independent venture capital investors in the UK is to manage and administer the newly launched...